PHARMING Aktie

 

Pharming announces 12 abstracts have been accepted for presentation at 2025 ACAAI Annual Scientific meeting being held in Orlando, Florida on November 6-10...

Pharming provides update on previously announced G&A expense reduction plan...

Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Pharming sNDA for leniolisib in children aged 4-11 years with APDS accepted and granted Priority Review by FDA....

KOPENHAGEN, Dänemark--(BUSINESS WIRE)--Neumirna Therapeutics, ein Biotech-Unternehmen, das RNA-basierte Therapien für neurologische Erkrankungen entwickelt, hat heute die Ernennung von Ellen K. Donnelly, Ph.D., zum Chief Executive Officer bekannt gegeben. Ellen bringt mehr als 20 Jahre Führungserfahrung auf dem Gebiet der Neurowissenschaften und seltenen Krankheiten mit, die sie bei globalen Pharmaunternehmen als auch bei innovativen Biotech-Firmen gesammelt hat. Ihr Wechsel zu Neumirna folgt auf ihre Tätigkeit als CEO von Abliva AB, das kürzlich von der Pharming Group übernommen wurde. Zuvor hatte sie die Leitung von Modus Therapeutics und Souvien Therapeutics inne. Eine frühere Station ihrer Karriere war Pfizer Inc., wo Ellen fast ein Jahrzehnt lang in leitenden Positionen in den Bereichen Neurowissenschaften, klinische Forschung, Portfoliomanagement und Strategie tätig war. Sie hat einen Ph.D. in Pharmakologie und Neurowissenschaften der Yale University. „Ellen vereint wissenschaftliche Exper...

COPENHAGEN, Denmark--(BUSINESS WIRE)--Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer. Ellen brings more than 20 years of leadership in neuroscience and rare diseases, spanning both global pharmaceutical companies and innovative biotech firms. She joins Neumirna from her role as CEO of Abliva AB, recently acquired by Pharming Group, and has previously led Modus Therapeutics and Souvien Therapeutics. Earlier in her career, Ellen spent nearly a decade at Pfizer Inc., where she held leadership roles in neuroscience research, clinical operations, portfolio management, and strategy. She holds a Ph.D. in Pharmacology & Neuroscience from Yale University. "Ellen combines scientific expertise with proven leadership in both biotech and pharma," said Luis Pareras, Chairman of the Board at Neumirna. "The Board is confident that under her guidance, Neumirna will...

Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025....

Das Instrument PHGN NL0010391025 PHARMING GRP EO-,01 EQUITY hat seinen ersten Handelstag am 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG LUX0, SettlCurr EUR, CCP Y The instrument PHGN NL0010391025 PHARMING GRP EO-,01 EQUITY has its first trading date on 05.09.2025: CONTINUOUS TRADING WITH AUCTIONS, PAG LUX0, SettlCurr EUR, CCP Y...

Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025....

Even in a choppy market, Zacks' strategies are spotlighting winners like Oracle, Intellia, and Pharming Group, proving the value of a disciplined, research-driven approach....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Leiden, the Netherlands, September 2, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025....

The average of price targets set by Wall Street analysts indicates a potential upside of 142.3% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

The average of price targets set by Wall Street analysts indicates a potential upside of 145.8% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conference in the month of August:...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Leiden, the Netherlands, July 31, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second quarter and first half year ended June 30, 2025....

For media and investors only...

Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved....